Using a scoring system that includes antibody levels, sex, age, and another antibody test predicts relapse risk better than using antibody levels alone, helping doctors make more informed decisions about when to stop medication.
Evidence from Studies
No evidence studies found yet.
What Would Prove This
Per GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this claim, ordered from strongest to weakest.
A meta-analysis of external validations could determine whether this nomogram generalizes across populations, assays, and healthcare systems.
Systematic review and meta-analysis of all external validations of the proposed nomogram (TSI, sex, age, TBII) in independent cohorts of Graves' disease patients, measuring calibration, discrimination (C-statistic), and net reclassification improvement compared to single biomarkers.
An RCT could test whether using the nomogram to guide treatment duration reduces relapse rates compared to standard care.
Multicenter RCT of 600 adults with Graves' disease, randomized to treatment decisions guided by the nomogram (extend ATD if score >111.4) vs standard care (withdraw ATD at euthyroidism). Primary outcome: relapse rate at 2 years.
A prospective cohort could validate the nomogram’s performance in real-world settings and assess its stability over time.
Prospective cohort of 400 adults with Graves' disease undergoing ATD withdrawal, with nomogram scores calculated at discontinuation. Primary outcome: relapse within 2 years, with calibration and discrimination assessed using Hosmer-Lemeshow and C-statistics.
A case-control study could identify which components of the nomogram contribute most to misclassification of relapse risk.
Case-control study of 150 patients misclassified by TSI alone (e.g., low TSI but relapsed) and 150 correctly classified, comparing nomogram component values to determine which factors best explain misclassification.
A cross-sectional analysis could compare nomogram scores between relapsers and non-relapsers to confirm the model’s discriminative power.
Cross-sectional analysis of nomogram scores in 300 adults with Graves' disease who have discontinued ATD for at least 1 year, comparing mean scores between those who relapsed and those who remained in remission.